pISSN 1738-6756   eISSN 2092-9900
Open Access, Peer-reviewed
    J Breast Cancer. 2006 Dec;9(4):309-316. Korean.
    Published online Dec 31, 2006.
    https://doi.org/10.4048/jbc.2006.9.4.309
    Copyright © 2006 Korean Breast Cancer Society
    Original Article

    Loss of Heterozygosity of Chromosome 17p13 and p53 Expression in Invasive Ductal Carcinomas

    Sook Hyun Lee, Seong Rae Kim, Chan Heun Park, Seong Jin Cho,1 and Young Hee Choi1
      • Department of Surgery, Hallym University College of Medicine, Seoul, Korea.
      • 1Department of Pathology, Hallym University College of Medicine, Seoul, Korea.
    Received August 07, 2006; Accepted November 10, 2006.

    Abstract

    Purpose

    The p53 gene is located on chromosome 17p13 and may play important roles in cell cycle regulation, apoptosis and the regulation of the expression of other genes as well as tumor suppression. In addition, the p53 gene is believed to play an important role in the progression of various human malignant tumors through mutation and overexpression. There have been few studies on loss of heterozygosity (LOH) study on 17p13 in invasive ductal carcinoma. This study evaluated a 17p13 LOH and protein expression in invasive ductal carcinomas and correlated these results with the clinicopathological factors.

    Methods

    LOH analysis was carried out using a polymerase chain reaction with four polymorphic microsatellite markers (D17S796, TP53, D17S5, D17S513) in 50 surgically resected tumors and their non-tumorous counterparts. The p53 protein expression level was examined using immunohistochemistry.

    Results

    A LOH and protein expression was detected in 66% and 54% of the tumors, respectively. The LOH rates ranged from 26.3% (D17S513) to 33.3% (TP53). There was no detected LOH or protein expression in the non-tumor parts. The LOH results correlate well with the tumor size and stage. The protein expression results correlate well with the tumor histological grade. There was no correlation between the LOH and protein loss.

    Conclusion

    17p13 LOH and p53 gene abnormalities may be associated with tumorigenesis and tumor invasion. In addition, the combined use of both methods may help in early detection as well as for determining the prognosis of an invasive ductal carcinoma. 17p13 LOH and p53 protein expression may contribute to tumor progression through reciprocal complementation in some portions of the invasive ductal carcinoma.

    Keywords
    Invasive ductal carcinoma; p53; less of Heterozygositym; Immunohistochemistry

    Figures

    Fig 1
    LOH at chromosome 17p13 loci in invasive ductal carcinoma. Representative D17S513 (left) and D17S5 microsatellite analysis of N (normal) and T (Tumor). Each T lane shows lower band loss (left) and considerable band loss (right).

    Fig 2
    Immunohistochemically, the tumor cells of invasive ductal carcinoma show strong nuclear expression.

    Tables

    Table 1
    DNA sequences of 4 microsatellites on 17p13

    Table 2
    Clinicopathologic findings of 50 invasive ductal carcinomas.

    Table 3
    17p13 LOH and p53 protein expression according to the clinicopathological factors

    Table 4
    Correlation between LOH & Protein Expression

    References

      1. 2002 Annual Report of the Central Cancer Registry in Korea. Republic of Korea: Ministry of Health and Welfare; 2003. pp. 11.
      1. Sparano JA, Fazzari MJ, Childs G. Clinical application of molecular profiling in breast cancer. Future Oncol 2005;1:485–496.
      1. Abrial C, Mouret-Reynier MA, Cure H, Feillel V, Leheurteur M, Lemery S, et al. Neoadjuvant endocrine therapy in breast cancer. Breast 2006;15:9–19.
      1. Lo S, Johnston SR. Novel systemic therapies for breast cancer. Surg Oncol 2003;12:277–287.
      1. Hollingsworth AB, Singletary SE, Morrow M, Francescatti DS, O'Shaughnessy JA, Hartman AR, et al. Current comprehensive assessment and management of women at increased risk for breast cancer. Am J Surg 2004;187:349–362.
      1. Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 2004;10:357–364.
      1. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001;10:139–152.
      1. Ingvarsson S. Molecular genetics of breast cancer progression. Semin Cancer Biol 1999;9:277–288.
      1. Liu MC, Gelmann EP. P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 2002;29:246–257.
      1. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell 2005;14:7–10.
      1. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001;13:332–337.
      1. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 2000;910:121–137.
      1. Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci 2006;11:1818–1843.
      1. Hall PA, McCluggage WG. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol 2006;208:1–6.
      1. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 2005;331:868–880.
      1. Morris SM. A role for p53 in the frequency and mechanism of mutation. Mutat Res 2002;511:45–62.
      1. Tsuji N, Furuse K, Asanuma K, Furuya M, Kondoh K, Kamagata C, et al. Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased survivin expression in breast cancer. Breast Cancer Res Treat 2004;87:23–31.
      1. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003;10:431–442.
      1. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 2006;13:951–961.
      1. Park JH, Kim SJ, Choi UJ, Lee KM. Correlation of the Immunohistochemical Coexpression of p53 and HER-2/neu and the Prognosis of Breast Cancer. J Breast Cancer 2005;8:41–47.
      1. Jo HJ, Yun KJ, Moon HB. Expression of p21, p53 and bcl-2 Proteins in Invasive Ductal Carcinoma of the Breast. Korean J Pathol 2003;37:393–399.
      1. Kim JK, Song YJ, Cho SI, Ryu DH, Yun HY, Sung RH. Clinicopathologic Significance of p53 and c-erbB-2 Protein Expression in Breast Carcinoma. J Korean Surg Soc 2002;62:282–287.
      1. Roncuzzi L, Brognara I, Baiocchi D, Amadori D, Gasperi-Campani A. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer. Oncol Rep 2005;14:471–474.
      1. Johnson SM, Shaw JA, Walker RA. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer 2002;98:205–209.
      1. Ding SL, Sheu LF, Yu JC, Yang TL, Chen BF, Leu FJ, et al. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade. Br J Cancer 2004;90:1995–2001.
      1. Otis CN, Krebs PA, Albuquerque A, Quezado MM, San Juan X, Sobel ME, et al. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features. Int J Surg Pathol 2002;10:237–245.
      1. Seitz S, Poppe K, Fischer J, Nothnagel A, Estevez-Schwarz L, Haensch W, et al. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J Pathol 2001;194:318–326.
      1. Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. Breast Cancer Res Treat 2001;66:135–142.
      1. Gentile M, Bergman Jungestrom M, Olsen KE, Soderkvist P, Wingren S. p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur J Cancer 1999;35:1202–1207.
      1. Suh KS, Lee YH, Na SY, Park MI, Kim HS, Lee SK. Mutational and Loss of Heterozygosity Analysis of the p53 and PTEN Tumor Suppressor Genes in Breast Carcinoma. Korean J Pathol 2005;39:313–319.
      1. Regitnig P, Moser R, Thalhammer M, Luschin-Ebengreuth G, Ploner F, Papadi H, et al. Microsatellite analysis of breast carcinoma and corresponding local recurrences. J Pathol 2002;198:190–197.
    MeSH Terms
    Apoptosis
    Carcinogenesis
    Carcinoma, Ductal*
    Cell Cycle
    Complement System Proteins
    Genes, p53
    Humans
    Immunohistochemistry
    Loss of Heterozygosity*
    Microsatellite Repeats
    Polymerase Chain Reaction
    Prognosis
    Metrics
    Share
    Figures
    slide
    slide

    1 / 2

    Tables
    slide
    slide
    slide
    slide

    1 / 4

    PERMALINK